NovoCure reported third-quarter net revenues of $193.4 million, a 16% increase year-over-year driven by 19% global active patient growth. The company raised its full-year 2026 revenue guidance to $736 million-$743 million and adjusted EBITDA guidance to $24 million-$34 million. NovoCure also announced that Optune Pax received approval in Japan for pancreatic cancer treatment and entered a clinical collaboration with Verastem Oncology. The company operates as a global oncology firm developing Tumor Treating Fields therapies.
